Novo Nordisk’s Wegovy Sales Shortfall: A Rare Setback for the Danish Drugmaker

Sales Disappointment::
Novo Nordisk's shares dropped by more than 7% on Wednesday due to Wegovy's missed sales expectations.

Pricing Pressure::
The sales shortfall is attributed to pricing pressure in the US market for Wegovy.

Sales Outlook Adjustment::
Despite the setback, Novo Nordisk has increased its sales outlook for the year, predicting a revenue rise of 22% to 28% at constant exchange rates.

Operational Impact::
The company's operating profit growth is expected to be between 20% and 28%, slightly lower due to an impairment charge from a failed drug.

Market Reaction::
The stock tumble marks a rare setback for Novo Nordisk, which has otherwise seen significant success with its blockbuster drugs like Wegovy and Ozempic.